Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 8963 results
Found 8963 results.

Adolescent

Gulick RM, Wilkin TJ, Chen YQ, et al. "Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial." Ann. Intern. Med.. 2017;167(6):384-393.
Hulgan T, Haubrich R, Riddler SA, et al. "European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142." AIDS. 2011;25(1):37-47.
Weinberg A, Park J-G, Bosch R, et al. "Effect of Depot Medoxyprogesterone Acetate on Immune Functions and Inflammatory Markers of HIV-Infected Women." J. Acquir. Immune Defic. Syndr.. 2016;71(2):137-45.
Van Epps P, Matining RM, Tassiopoulos K, et al. "Older age is associated with peripheral blood expansion of naïve B cells in HIV-infected subjects on antiretroviral therapy." PLoS ONE. 2014;9(9):e107064.
Stapleton JT, Chaloner K, Zhang J, et al. "GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy." AIDS. 2009;23(5):605-10.
Jacobson JM, Zheng L, Wilson CC, et al. "The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection." J. Acquir. Immune Defic. Syndr.. 2016;71(2):163-71.
Daar ES, Tierney C, Fischl MA, et al. "Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1." Ann. Intern. Med.. 2011;154(7):445-56.
Evans SR, Ellis RJ, Chen H, et al. "Peripheral neuropathy in HIV: prevalence and risk factors." AIDS. 2011;25(7):919-28.
Yeh T-min, Evans SR, Gulick RM, Clifford DB. "Vicriviroc and peripheral neuropathy: results from AIDS Clinical Trials Group 5211." HIV Clin Trials. 2010;11(1):51-8.
Johnson DC, Chasela C, Maliwichi M, et al. "Tenofovir use and renal insufficiency among pregnant and general adult population of HIV-infected, ART-naïve individuals in Lilongwe, Malawi." PLoS ONE. 2012;7(7):e41011.
Riddler SA, Haubrich R, A DiRienzo G, et al. "Class-sparing regimens for initial treatment of HIV-1 infection." N. Engl. J. Med.. 2008;358(20):2095-106.
Stüve O, Marra CM, Bar-Or A, et al. "Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis." Arch. Neurol.. 2006;63(10):1383-7.
Acosta EP, Kendall MA, Gerber JG, et al. "Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily." Antimicrob. Agents Chemother.. 2007;51(9):3104-10.
Dooley KE, Savic RM, Park J-G, et al. "Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers." Antimicrob. Agents Chemother.. 2015;59(6):3399-405.
Kalayjian RC, Spritzler J, Matining RM, et al. "Older HIV-infected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reduction." AIDS. 2013;27(10):1563-71.
Graham CS, Wells A, Liu T, et al. "Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection." AIDS. 2006;20(3):345-51.
Sax PE, Tierney C, Collier AC, et al. "Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy." N. Engl. J. Med.. 2009;361(23):2230-40.
Tenorio AR, Chan ES, Bosch RJ, et al. "Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286." J. Infect. Dis.. 2015;211(5):780-90.
Evans SR, Lee AJ, Ellis RJ, et al. "HIV peripheral neuropathy progression: protection with glucose-lowering drugs?" J. Neurovirol.. 2012;18(5):428-33.
Erlandson KMace, Kitch D, Tierney C, et al. "Impact of randomized antiretroviral therapy initiation on glucose metabolism." AIDS. 2014;28(10):1451-61.
Livingston EG, Cohn SE, Yang Y, et al. "Lipids and lactate in human immunodeficiency virus-1 infected pregnancies with or without protease inhibitor-based therapy." Obstet Gynecol. 2007;110(2 Pt 1):391-7.
Cohn SE, Umbleja T, Mrus J, Bardeguez AD, Andersen JW, Chesney MA. "Prior illicit drug use and missed prenatal vitamins predict nonadherence to antiretroviral therapy in pregnancy: adherence analysis A5084." AIDS Patient Care STDS. 2008;22(1):29-40.
Court R, Gordon M, Cohen K, et al. "Random lopinavir concentrations predict resistance on lopinavir-based antiretroviral therapy." Int. J. Antimicrob. Agents. 2016;48(2):158-62.
Liu H, Wilson IB, Goggin K, et al. "MACH14: a multi-site collaboration on ART adherence among 14 institutions." AIDS Behav. 2013;17(1):127-41.
Canter JA, Robbins GK, Selph D, et al. "African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy." J. Infect. Dis.. 2010;201(11):1703-7.
Mugavero MJ, May M, Ribaudo HJ, et al. "Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study." J. Acquir. Immune Defic. Syndr.. 2011;58(3):253-60.
Mitsuyasu R, Gelman R, Cherng DWeng, et al. "The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328." Arch. Intern. Med.. 2007;167(6):597-605.
Taiwo B, Zheng L, Gallien S, et al. "Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)." AIDS. 2011;25(17):2113-22.
Wagner GJ, Goggin K, Remien RH, et al. "A closer look at depression and its relationship to HIV antiretroviral adherence." Ann Behav Med. 2011;42(3):352-60.
Gross R, Tierney C, Andrade A, et al. "Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial." Arch. Intern. Med.. 2009;169(13):1224-32.

Pages